Strumento inattivo

Altre lingue Organovo Holdings Inc Nyse

Azioni

US68620A1043

Prezzo di chiusura Nyse Altri mercati azionari
- ^USD	-

31/05	Organovo Holdings, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 marzo 2024	CI
15/04	Il farmaco di Organovo per le malattie del fegato grasso raggiunge l'obiettivo principale in uno studio di metà fase	RE

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	31/05
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease	21/05
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)	14/05
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering	09/05
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	16/04
Organovo's fatty liver disease drug meets main goal in mid-stage study	15/04
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	15/04
Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	15/04
Organovo: Fiscal Q3 Earnings Snapshot	08/02
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress	25/01
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings	25/01
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress	09/01
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results	06/12
Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results	06/12
Organovo: Fiscal Q2 Earnings Snapshot	10/11
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
Organovo Highlights FXR314 Combination Therapy Potential and Plan	08/11
Organovo Holdings, Inc. Highlights FXR314 Combination Therapy Potential and Plan	08/11
Organovo : Submission of Matters to a Vote of Security Holders - Form 8-K	03/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Organovo Holdings Inc Nyse

Azioni

US68620A1043

Altre lingue

Filtri